David Jensen
Publishes 1 feed
The California Stem Cell Report
An inside and independent look at the Golden State's $12 billion stem cell research program, how it works, who wins and who loses, its conflicts of interest and its changing priorities.
10 posts · theirs
Lately
Looking for Work? Want to Help Give Away Billions of Dollars?
Capricor Stock Jumps 59 Percent as Firm Maneuvers to Win Approval of Duchenne Treatment
LinkedIn Video, Transparency, Accessibility: The View from the Stem Cell Trenches at CIRM
Capricor in Trouble with Feds But California Stands Apart from the Ruckus Despite $18 Million Taxpayer Investment. Why?
Political Media Tackle $12 Billion California Ballot Measure for Immunology Research
Capricor Committed to Winning Federal Go-Ahead on Treatment for Deadly Affliction that Attacks Boys and Young Men
Capricor's Treatment for Deadly Muscle-Wasting Disease Rebuffed by FDA Advisory Committee
FDA-Capricor Hearing: Patients Tell a Story of Loss and Unstoppable Muscle Deterioration
Capricor-FDA Hearing: Public to be Heard Next, Vote on Capricor May Come by Midafternoon
FDA Capricor Hearing: Company Says Lightning Does Not Strike Three Times in Same Place
Everything on this page was read from markup David Jensen published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON